Yogenthiran Saunthararajah, MD of Cleveland Clinic gives an overview of his abstract, Phase 1 Evaluation of Oral Tetrahydrouridine-Decitabine As Non-Cytotoxic Epigenetic Disease Modification for Sickle Cell Disease, that was presented at the 58th ASH Annual Meeting in San Diego, CA.
Evaluation of Oral Tetrahydrouridine- Decitabine As Non- Cytotoxic Epigenetic Disease Modification for Sickle Cell Disease
